The T1D Index, a data simulation tool, measures the human and public health impact of type 1 diabetes globally. Simulations suggest over 3.86 million 'missing people' and 32 healthy years lost due to T1D, highlighting the need for interventions such as timely diagnosis, accessible care, and research funding.
A new study aims to reduce diabetes-related distress in young adults with T1D using telemedicine-delivered cognitive behavioral therapy. The study will recruit 150 participants aged 18-30 and evaluate its effectiveness in improving blood-sugar control.
The JDRF, Lupus Research Alliance and National Multiple Sclerosis Society have launched a joint grant program to investigate the immune system's role in autoimmune diseases. The program aims to identify common mechanisms that cause or contribute to the development of lupus, T1D, and MS.
The JDRF Center of Excellence in New England will focus on accelerating gene editing approaches for beta cell replacement therapy, aiming to solve the problem of immune rejection of beta cells. The center will collaborate with leading Massachusetts-based experts to develop new technologies and strategies to prevent beta cell destructio...
A recent study published in the New England Journal of Medicine found that teplizumab significantly delayed the onset of type 1 diabetes by three years compared to a placebo. The trial involved individuals at high risk of developing T1D, and those treated with teplizumab showed higher rates of insulin secretion and C-peptide levels.
Researchers identified two classes of compounds that prevent most of the effects of interferon-α on human beta cells, paving the way for potential clinical trials. IFN-α promotes rapid changes in chromatin accessibility, which may contribute to triggering autoimmunity and type 1 diabetes.
A study funded by JDRF, ADA, and Helmsley found all human and analog insulins in US pharmacies contained the expected amount of active insulin, posing no safety risks for people with diabetes.
The Juvenile Diabetes Research Foundation (JDRF) honored five researchers for their outstanding contributions to type 1 diabetes research, including breakthroughs in beta cell autoimmunity and immune therapies. The awards recognize significant progress toward curing T1D, with funded research totaling over $2.2 billion.
Research shows that widespread screening for islet autoantibodies significantly reduces the occurrence of life-threatening DKA among children with pre-symptomatic T1D. The study screened 90,632 children in Bavaria, Germany and found a lower prevalence of DKA compared to unscreened children.
JDRF has committed 23 training grants totaling over $8 million to accelerate T1D research. These grants will support early-career scientists working on groundbreaking treatments for T1D, including ultra-fast insulins and immunotherapies.
A pilot study will evaluate advanced artificial pancreas technology for individuals with type 1 diabetes under real-world conditions. The study aims to test the safety and effectiveness of an unsupervised artificial pancreas system that automatically controls insulin delivery.
Researchers developed a non-invasive imaging technique to track beta cell status in type 1 diabetes patients. The PET scan detects the amount of radiotracer in the pancreas, indicating the overall amount or volume of active beta cells present.
Researchers have discovered a potential therapeutic target for preserving beta cell health in people with type 1 diabetes, according to a new JDRF-funded study. The MANF protein has been shown to reduce beta cell stress and promote regeneration.
A decade-long study reveals that nearly 70% of children with multiple islet autoantibodies developed T1D within 10 years, highlighting the importance of pre-diabetes research. The study also found that progression of the disease was faster for those who showed the presence of antibodies at younger than three years old.
A study published in Cell Metabolism identified a single gene mutation in SIRT1 as a potential cause of type 1 diabetes. The research found that the mutated gene led to impaired beta cell function and increased susceptibility to diabetes.
Researchers aim to develop a biologic cure for diabetes by addressing immunosuppression, poor islet viability, and implantation issues. The new funding will support the development of bioactive scaffolds and conformal coatings to protect implanted cells from the immune response.
Researchers at Oregon Health & Science University and Legacy Health have discovered a method to stabilize liquid glucagon, enabling its use in standard diabetes pumps. This breakthrough could lead to future-generation artificial pancreas systems that dispense both insulin and glucagon for optimal glucose control.
A study by Joslin Diabetes Center found that a significant number of people with long-term type 1 diabetes developed little to no diabetic eye disease over time. The researchers hope to identify the factors behind this protection, which could lead to new treatments or prevention strategies.
The prevalence of Type 1 diabetes among young people in the US has increased by 23% between 2001 and 2009, according to a new study. Researchers funded by organizations like JDRF are making progress in treatments, technology, and vaccines, but more support is needed to combat this life-threatening disease.
The iDEAL study is a Phase II clinical trial evaluating the safety and efficacy of iCo-007 in treating diabetic macular edema. The trial aims to improve visual acuity in patients with DME, a leading cause of blindness in working Americans.
Scientists discover that cellular stress takes place in pancreatic beta cells before T1D onset, potentially igniting autoimmune attack. ER stress response may contribute to beta cell dysfunction and death, shedding light on disease progression and potential therapeutic targets.
A new JDRF-funded study identifies genes expressed in beta cells, suggesting a role in their own destruction leading to T1D. The research may help explain why the immune system specifically attacks beta cells, opening up new avenues for understanding and treating the disease.
The REMOVAL study aims to test whether metformin can prevent or reduce the risk of cardiovascular complications in people with type 1 diabetes. The five-year trial will follow 500 patients and examine the effects of metformin on blood glucose control, treatment satisfaction, and other complications.
Scientists at Stanford University have identified a molecular pathway responsible for the decline of beta cell division with age. By manipulating this pathway, they can restore the ability of older beta cells to divide and generate new cells, potentially leading to breakthroughs in treating both type 1 and type 2 diabetes.
JDRF-funded researchers identify a protein and chemical compound that stimulate beta cell growth, providing a new drug target for diabetes treatment. The discovery may lead to the development of tests to measure beta cell number using Tmem27 fragments as a biomarker.
A study by researchers funded by JDRF found that the serotonin hormone increases insulin-producing beta cells during pregnancy. This discovery could lead to the development of new drugs to promote beta cell regeneration in people with type 1 diabetes, offering a potential cure for the disease.
Researchers developed a nanovaccine to stop aggressive immune attack on beta cells, restoring normal blood sugar levels in humanized mouse models. The treatment targeted specific immune cells without compromising the rest of the immune system.
Scientists found that alpha cells can spontaneously reprogram into beta cells, restoring insulin production and potentially treating type 1 diabetes. The study demonstrated that removing nearly all beta cells allowed the pancreas to regenerate new ones, offering a new strategy for regenerating insulin-producing cells.
Researchers tested mecamylamine, a topical drug, in a human clinical trial to treat diabetic macular edema. The study showed significant improvement in vision and biological effects in the retina in approximately 40% of participants.
Researchers at the University of Cambridge found that first-generation artificial pancreas systems can lower risk of low blood sugar emergencies while sleeping and improve diabetes control. The study showed improved target blood glucose levels, minimized low blood sugars, and reduced hypoglycemia.
Researchers at the Salk Institute for Biological Studies have made a breakthrough in understanding how stress hormones affect insulin-producing cells. The study found that the hormone CRF can increase the rate of cell growth and proliferation, which could potentially lead to new approaches for treating type 1 diabetes.
The study found that regular CGM use is the primary factor in achieving better diabetes control, regardless of age. People using CGM devices six days per week or more showed similar levels of improvement in diabetes control across all age groups, from children to adults.
Scientists have discovered a way to regenerate insulin-producing beta cells from non-insulin-producing alpha cells, offering new hope for treating type 1 diabetes. The research found that modifying the expression of a specific gene in alpha cells can drive their conversion into functional beta cells.
A study found that continuous glucose monitoring (CGM) devices enable people with excellent blood sugar control to continue managing their diabetes while reducing the frequency of low blood sugar events. CGM devices helped participants spend more time in the target blood sugar range and reduced biochemical hypoglycemia.
JDRF-funded researchers have identified compounds that can stimulate insulin-producing cells in the pancreas, paving the way for potential regenerative medicines for type 1 diabetes. The study found two compounds that promote beta cell replication via different biological pathways.
Researchers describe a potential new therapeutic approach for diabetic retinopathy using ASP-440, a protease plasma kallikrein inhibitor. The study showed significant reductions in retinal vascular permeability and blood pressure in rodents, suggesting promising results for treating the condition.
JDRF-funded researchers at the University of Pittsburgh School of Medicine discovered a protein called cdk6 that regulates human beta cell replication. This finding provides proof-of-principle for stimulating human beta cell production and function.
Researchers at UCSF used kinase inhibitors to block and reverse type 1 diabetes in mice, showing potential for new therapeutic approach. The study found that 80% of mice with established diabetes reversed symptoms after two months of treatment.
A DNA vaccine, BHT-3021, is being developed to reverse the immune response causing type 1 diabetes. The vaccine has shown safety and preliminary data indicate it may preserve beta cells and induce immune tolerance.
SmartCells' SmartInsulin is a once-a-day, glucose-regulated insulin that maintains continuous blood glucose control while reducing hypoglycemia risk. JDRF's $1M funding supports preclinical safety and efficacy testing for this treatment, aiming to improve patient safety and quality of life.
A JDRF-funded study suggests that exposure to certain bacteria may provide protection against developing type 1 diabetes. Researchers found that mice exposed to these harmless microbes had a lower risk of autoimmune disorders. The findings lend support to the 'hygiene hypothesis' and may lead to new therapeutic approaches for prevention.
A multicenter clinical trial funded by the Juvenile Diabetes Research Foundation found that continuous glucose monitoring significantly improved blood sugar control in patients with type 1 diabetes. HbA1c levels decreased by an average of 0.53% in patients aged 25 and older, while improvements were not observed in younger age groups.
The JDRF Scholar Award is granted to individual scientists who exhibit a unique creative vision and approach to research. Dr. Jeffrey Bluestone and Dr. Mark Cooper are the recipients of this prestigious award, which provides them with $250,000 annually for up to five years to conduct specialized research.
A team of Florida scientists, including Mark Atkinson, Michael Haller, and Desmond Schatz, have received the sixth annual Excellence in Clinical Research Award from JDRF International. The award recognizes their innovative work on using umbilical cord blood stem cells and drug treatments to prevent and reverse type 1 diabetes.
This year’s JDRF award recipients are Dr. Michael Brownlee for his work on the biochemical basis of diabetic complications, Dr. Maike Sander for her understanding of insulin-producing cells, and Dr. Michael German for his research on pancreatic beta cell structure and development.
The READ-2 study, a collaboration between JDRF, Johns Hopkins, and Genentech, found that ranibizumab injections significantly improved visual acuity and reduced excess retinal thickness in patients with diabetic macular edema. The treatment resulted in a 56% reduction in retinal thickness compared to laser photocoagulation therapy.
Researchers are exploring the potential of generating insulin-producing cells using adult stem cells to treat type 1 diabetes. The partnership aims to restore normal blood sugar levels through autologous cell transplantation, eliminating the need for immunosuppressive agents.
The JDRF Autoimmunity Center will focus on developing novel antigen-specific approaches to predict, prevent, and possibly reverse type 1 diabetes. The center will utilize the Barbara Davis Center's resources in collaboration with JDRF to create therapies specifically aimed at immunoprevention of type 1 diabetes.
Scientists at JDRF have identified a new pancreatic progenitor cell capable of generating insulin-producing beta cells. These cells, similar to embryonic progenitors, show promise for regenerating lost beta cells in people with type 1 diabetes.
Professor Jens Høiriis Nielsen from the University of Copenhagen receives a JDRF research grant to investigate beta cell expansion during pregnancy. The goal is to discover new approaches for treating type 1 diabetes, potentially leading to regenerative drugs and therapies.